News | August 29, 2011

European Society of Cardiology Releases New PAD Guidelines

August 29, 2011 — The Guidelines on Peripheral Artery Disease (PAD) are the first document produced by the European Society of Cardiology (ESC) to address all aspects of peripheral atherosclerotic disease, excepting the aorta. The document does include disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. It is the result of close collaboration between physicians from many different areas of expertise: cardiology, neurology, radiology, vascular surgery, and vascular medicine.

The document covers general issues such as epidemiology, risk factors, diagnostic approaches, and general rules for treatment. The detailed clinical presentations are then discussed in specific sections for each vascular site. Particular emphasis is placed on multi-site artery disease, such as patients with coronary artery disease (CAD) and disease in another vascular bed. The document ends with a list of significant gaps in evidence, which will hopefully stimulate new research.

The section on treatment modalities in patients with CAD covers medical therapy, surgery, and endovascular techniques. The guidelines clearly differentiate management of symptomatic and asymptomatic patients. In patients with symptomatic disease, neurological assessment and appropriate treatment should be proposed as soon as possible after the index event.

The document also addresses clinical presentation, diagnostic modalities, prognosis and treatment in patients with upper extremity, mesenteric and renal artery disease.

The guidelines extensively cover diagnosis (with an emphasis on the importance of the ankle-brachial index) and treatment, with endovascular or surgical techniques, in patients with lower extremity artery disease (LEAD). It differentiates between those suffering from claudication and those with critical limb ischemia. It emphasizes the importance of adequate balance between supervised exercise and best medical therapy as compared to revascularization in patients with LEAD. This takes into account the level of disability and the localization of disease.

Another section concerns management of patients with multi-site artery disease (MSAD). Indeed, although patients with MSAD are encountered regularly in clinical practice, no randomized trials have been designed to compare different treatment strategies. From a clinical perspective, the document emphasizes the need for an increased awareness of the possibility of atherosclerotic disease occurring at sites other than the presenting one. It also stresses that, when dealing with an MSAD patient, physicians must focus on overall clinical status as well as lesion sites and technical difficulties related to specific treatment options. This accounts for the presence of all cardiovascular risk factors and co-morbidities.

In conclusion, the new guidelines will help physicians manage most common aspects of PAD from a variety of complex clinical scenarios encountered in clinical practice. They emphasize that management of patients with PAD should always be decided after multidisciplinary discussion, also including specialists beyond the area of cardiovascular medicine. Examples might include neurologists or nephrologists. This was also the way in which current guidelines were created.

The guidelines will be formally introduced at a special session of the ESC Congress 2011 in Paris on Aug. 29.

For cardiologists, coronary artery disease is the most important presentation of atherosclerosis. Patients with CAD may also have symptomatic or asymptomatic atherosclerosis in other vascular areas (peripheral artery disease).

The presence of atherosclerotic disease at one vascular site increases the likelihood of the disease at another site. In the elderly, who constitute the dominant part of patient population, the overlap of CAD, cerebrovascular disease and LEAD is particularly high. In consequence, increasing numbers of patients with heart disease require assessment for problems in other vascular sites. On the other hand, a substantial proportion of patients with peripheral artery diseases will die from CAD.

For more information: www.escardio.org

Related Content

FDA Panel Recommends Continued Use of Paclitaxel-coated Peripheral Devices
Feature | Peripheral Artery Disease (PAD) | August 28, 2019 | Jeff Zagoudis, Associate Editor
The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the safety of paclitaxel-...
New Report Says Concept Medical Positioned to Disrupt Peripheral Market
News | Peripheral Artery Disease (PAD) | August 27, 2019
Concept Medical was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA)...
PAD Intervention Patients on Statins Less Likely to Face Amputation
News | Peripheral Artery Disease (PAD) | August 23, 2019
Patients with peripheral artery disease (PAD) were significantly less likely to face amputation after surgical...
Concept Medical Granted FDA Breakthrough Device Designation for MagicTouch PTA Sirolimus Coated Balloon
News | Peripheral Artery Disease (PAD) | August 14, 2019
Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food and Drug...
New AHA Statement Highlights Need for Early Diagnosis, Treatment With Critical Limb IschemiaCTA image of a patient with severe peripheral artery disease (PAD) viewed on a tablet device using Siemens syngo.via webviewer.

CTA image of a patient with severe peripheral artery disease (PAD) viewed on a tablet device using Siemens syngo.via webviewer. PAD can lead to CLI.

News | Peripheral Artery Disease (PAD) | August 13, 2019
Non-invasive techniques and devices for assessing blood flow and other diagnostic considerations for people with ...
Endovascular-first Approach Equal to Open Surgery in Avoiding Amputation for Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | August 01, 2019
Less-invasive procedures to open severely clogged leg arteries were as good at helping people survive and avoid...
Annual U.S. Economic Burden of Critical Limb Ischemia Exceeds $200 Billion
News | Peripheral Artery Disease (PAD) | July 17, 2019
A new analysis published by The Sage Group LLC concludes that the all-cause cost of critical limb ischemia (CLI)...
Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack Endovascular System. This is a purpose-built dissection repair device implanted post-angioplasty in patients with peripheral arterial disease (PAD).
Technology | Peripheral Artery Disease (PAD) | April 15, 2019
April 15, 2019 – Intact Vascular Inc. received U.S.
The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003
Overlay Init